MeiraGTx Announces Participation at Upcoming Investor Conferences
BofA Securities 2021 Virtual Health Care Conference
Wednesday, May 12, 2021, 1:15 p.m. ET
2021 RBC Capital Markets Global Healthcare Conference
Wednesday, May 19, 2021, 4:50 p.m. ET
Oppenheimer s Rare & Orphan Disease Summit
Friday, May 21, 2021 (1x1 meetings only)
Live webcasts of the presentations. For conferences that offer replays, presentations will be made available for a limited time.
About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across
Investegate |MeiraGTx Announcements | MeiraGTx: MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
MeiraGTx to Present at Chardan 5th Annual Genetic Medicines Manufacturing Summit
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
MeiraGTx Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Preparing to Initiate Phase 3 Lumeos Clinical Trial in AAV-RPGR
- Announced Positive Preliminary Clinical Data from AQUAx AAV-hAQP1 Phase 1 Trial for Treatment of Grade 2/3 Xerostomia
- Completed Build of Internal cGMP Plasmid and DNA Manufacturing Facility
- Strengthened Balance Sheet and Extended Cash Runway into Mid-2023
- First in-vivo Data from Riboswitch Gene Regulation Platform to be Presented in 2021
LONDON and NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent progress.
MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by U.S. FDA for Treatment of Achromatopsia
LONDON and NEW YORK, Jan. 26, 2021 (GLOBE NEWSWIRE) MeiraGTx Holdings Plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the
CNGA3 gene.
ACHM is an inherited retinal disease that severely limits a person s sight by preventing cone photoreceptors in the eye from functioning. Individuals with ACHM are often legally blind from birth and have extremely debilitating sensitivity to light. AAV-CNGA3 is an investigational gene therapy treatment designed to restore cone function, delivered to the cone receptors at the back of the eye via subretinal injection.